SeqOne, a French innovator in AI-driven genomic evaluation, in the present day introduced it has entered right into a definitive settlement to accumulate Congenica, the UK firm spun out of the Wellcome Sanger Institute.
The acquisition is ready to create the “largest world software program pure participant within the genomics area“, serving over 160 labs in additional than 30 international locations.
“The speedy tempo of personalised drugs calls for steady funding in software program innovation and deep specialisation,” stated Martin Dubuc, CEO of SeqOne. “By integrating Congenica’s world-class workforce, we’re additional enhancing our robust progress trajectory and talent to offer market-leading software program to clients, knowledgeable interpretation companies, and deepening our presence within the UK market – a world chief in medical genomics for the reason that landmark 100,000 Genomes Challenge.”
Based in 2012, Congenica brings medical experience and expertise servicing over 25 non-public and public labs, together with a number of NHS Genomics Laboratory Hubs and nationwide programmes corresponding to Genomics England and the Hong Kong Genomic Programme.
Based in 2017, SeqOne is an AI-powered genomic evaluation platform, offering medical decision-support instruments that allow molecular laboratories to ship quick, correct, and scalable evaluation of genetic information for functions in oncology, uncommon and inherited illnesses, and infectious illnesses.
The acquisition unites SeqOne’s AI-powered platform for Subsequent-Technology Sequencing (NGS) evaluation with Congenica’s medical resolution help know-how and medical interpretation companies. The built-in providing will remodel advanced genomic information into speedy, actionable insights, in the end accelerating analysis for households affected by uncommon illness and enabling extra exact, personalised most cancers therapies.
This transfer comes at a crucial inflection level in drugs. The value to sequence a human genome has plummeted, creating an information tsunami. For hospitals and labs worldwide, the problem is not producing information, however deciphering it. This ‘interpretation bottleneck’ is reportedly the only largest barrier to delivering personalised drugs.
“Congenica has been an instrumental companion to Genomics England, significantly in advancing uncommon illness analysis via their strong platform for medical entire genome evaluation,” stated Dr Richard Scott, Chief Government Officer at Genomics England. “We look ahead to persevering with this vital work with the mixed experience of the SeqOne workforce to ship advantages for sufferers.”
The acquisition comes on the heels of a interval of intense natural progress for SeqOne, which has seen the corporate reortedly double its income and broaden its worldwide presence from three to over 30 international locations in simply 12 months.
It additionally follows the acquisition of Life & Comfortable in April, which expanded the corporate’s capabilities into multi-omics and virology. This momentum, supercharged by a €20 million funding spherical, has enabled SeqOne to execute its technique to consolidate a fragmented market and construct the definitive software program working system for the medical genomics revolution.
The mixed entity can have a considerably expanded world footprint:
- Serving over 160 buyer laboratories in additional than 30 international locations.
- Comprising a devoted workforce of over 125 workers.
- Enabling over 200,000 affected person genomic analyses in 2025 – a threefold enhance over 2024.
SeqOne is dedicated to making sure continuity of service and help for all Congenica clients, who will acquire entry to an expanded and built-in product portfolio. SeqOne will keep a significant UK presence on the Wellcome Sanger Institute.
“The Board of Congenica is pleased with the immense influence our know-how has had on healthcare since our inception,” stated Dr Andy Richards CBE, Chairman of Congenica. “We help this mix with SeqOne, believing their imaginative and prescient and sources are finest positioned to hold that legacy ahead and guarantee our progressive platform continues to thrive and serve sufferers globally.”
